A RANDOMIZED DOUBLE-BLIND PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM- BASED THERAPY AS FIRST LINE TREATMENT OF STAGE III OR IV NON-MUCINOUS EPITHELIAL OVARIAN CANCER

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Ovarian Cancer
  • Age: Between 18 - 100 Years
  • Gender: Female
  • Other Inclusion Criteria:
    1) Patients with a histologically confirmed diagnosis of nonmucinous epithelial ovarian cancer (serous, endometrial, clear cell, carcinosarcoma, and mixed pathologies) that is FIGO Stage III or IV. 2) Patients must provide a blood sample for molecular testing at screening. 3) Patient must provide a tumor tissue sample at screening for molecular testing.

You may not be eligible for this study if the following are true:

  • 1) Patients with mucinous, germ cell, transitional cell, or undifferentiated tumor. 2) Patients with low-grade / grade 1 epithelial ovarian cancer. 3) Stage III patients with no residual disease after primary surgery. 4) Patient who have not adequately recovered from prior major surgery.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.